Analysts Set Zura Bio Limited (NASDAQ:ZURA) PT at $15.80

Zura Bio Limited (NASDAQ:ZURA) has earned an average recommendation of “Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $15.80.

ZURA has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital lowered their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Tuesday, December 24th. Finally, Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th.

Zura Bio Trading Down 6.4 %

NASDAQ ZURA opened at $2.50 on Wednesday. The business’s fifty day moving average is $3.38 and its 200-day moving average is $3.64. Zura Bio has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities analysts predict that Zura Bio will post -0.65 EPS for the current year.

Insider Activity at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 22.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

A number of institutional investors have recently added to or reduced their stakes in ZURA. Braidwell LP bought a new position in shares of Zura Bio in the 3rd quarter worth $10,040,000. Point72 Asset Management L.P. bought a new position in Zura Bio in the second quarter valued at $8,446,000. Great Point Partners LLC raised its position in Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Armistice Capital LLC lifted its stake in Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Zura Bio in the 3rd quarter worth about $2,999,000. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.